** Brokerage Stifel resumes coverage on drug developer Soleno Therapeutics SLNO.O with a "buy" rating and a PT of $74
** SLNO's experimental rare-disease drug DCCR has an 80% chance of an FDA approval for the treatment of a rare genetic disorder known as Prader-Willi syndrome - brokerage
** Prader-Willi syndrome affects parts of the body with constant hunger, cognitive impairment and behavioral issues
** Brokerage believes that the FDA will be flexible in the approval process, given the significant unmet need for this rare disease
** We expect sales exceeding $1.5 billion, given that the loss of exclusivity is not expected until the mid-2030s - Stifel
** "We model a blockbuster opportunity that implies meaningful potential upside to the stock. We also think M&A is likely a plausible upside case as well" - Stifel analysts
** Stock down 5% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。